| 20 0.03 (0.15%) | 04-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 23.36 | 1-year : | 27.28 |
| Resists | First : | 20 | Second : | 23.36 |
| Pivot price | 19.97  |
|||
| Supports | First : | 19.9 |
Second : | 19.84 |
| MAs | MA(5) : | 19.99 |
MA(20) : | 19.94 |
| MA(100) : | 17.23 |
MA(250) : | 15.69  |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 100 | D(3) : | 98.1 |
| RSI | RSI(14): 76 | |||
| 52-week | High : | 20 | Low : | 12.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CSII ] has closed below upper band by 27.4%. Bollinger Bands are 94.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 20.05 - 20.15 | 20.15 - 20.23 |
| Low: | 19.72 - 19.86 | 19.86 - 19.97 |
| Close: | 19.81 - 20.02 | 20.02 - 20.18 |
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Thu, 11 Dec 2025
Cardiovascular Products and Solutions | Medical Devices for the Heart | Abbott U.S. - Abbott
Mon, 04 Aug 2025
Navigating Shockwave Medical: Applicant Admitted Prior Art, Standing, and Obviousness - JD Supra
Wed, 30 Jul 2025
Shockwave takes a hit on a lithotripsy patent in CSI dispute - BioWorld MedTech
Tue, 15 Jul 2025
CAFC Finds IPR Petitioner Did Not Rely on AAPA as Basis for Obviousness Grounds in Affirming PTAB Invalidation - IPWatchdog.com
Fri, 28 Apr 2023
Abbott completes $850M acquisition of Minnesota-based Cardiovascular Systems - Cardiovascular Business
Wed, 15 Feb 2023
Abbott to Acquire Cardiovascular Systems, Inc. - Diagnostic and Interventional Cardiology
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 89.6 (%) |
| Shares Short | 1,740 (K) |
| Shares Short P.Month | 1,810 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | -15.8 % |
| Operating Margin | -16.1 % |
| Return on Assets (ttm) | -7.6 % |
| Return on Equity (ttm) | -15.2 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 4.09 |
| Sales Per Share | 5.68 |
| EBITDA (p.s.) | -0.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -20.84 |
| PEG Ratio | 0.9 |
| Price to Book value | 3.5 |
| Price to Sales | 3.51 |
| Price to Cash Flow | -28.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|